Anders L. Carlson MD
Medical Director, International Diabetes Center; Medical Director, Diabetes Program HealthPartners; Assistant Professor, University of Minnesota Medical School, Minneapolis, Minnesota; Consultant in Endocrinology, HealthPartners, St. Paul, Minnesota
Anders Carlson, MD, is Medical Director at the International Diabetes Center (IDC) in Minneapolis, MN since 2015. As Medical Director, he helps conduct clinical trials, create and review educational programs and direct health system policies. Since 2010 he has been an adult endocrinologist and assistant professor in the University of Minnesota Medical School, where he remains active with clinical and pre-clinical teaching duties.
Dr. Carlson’s research includes work on several automated insulin delivery systems/artificial pancreas technology. In addition to serving as an investigator on several large NIH-funded studies including EDIC, GRADE and FLAIR, he also has worked on novel insulin formulations, glucose monitoring devices, and non-insulin pharmacotherapies. Other areas of focus include steroid-induced hyperglycemia in patients with cancer receiving chemotherapy and use of continuous glucose monitoring (CGM) in new clinical settings. Along with colleagues at IDC, he continues working on the standardization of glucose reports using the Ambulatory Glucose Profile (AGP). Finally, Dr Carlson recently received a grant from JDRF to investigate the use of intranasal insulin as a therapeutic approach to treating hypoglycemia unawareness in patients with type 1 diabetes.
Prior to working at IDC, as a practicing endocrinologist he helped launch a telehealth program in partnership with primary care and diabetes education based on the model of “training-the-trainer”, and remains active in that program to this day. He completed endocrinology, diabetes and metabolism fellowship at the University of Vermont.
Dr. Carlson has been involved at the national level as a member of the American Diabetes Association’s Prevention Committee and also in the Endocrine Society’s Task Force for Technology in T1D. He has published several papers related to diabetes, including a review of the use of CGM in T2D. He has been named a “Rising Star” physician in Minneapolis/St. Paul and as a “Best Doctor” in Minnesota Monthly.
Dr. Carlson’s research includes work on several automated insulin delivery systems/artificial pancreas technology. In addition to serving as an investigator on several large NIH-funded studies including EDIC, GRADE and FLAIR, he also has worked on novel insulin formulations, glucose monitoring devices, and non-insulin pharmacotherapies. Other areas of focus include steroid-induced hyperglycemia in patients with cancer receiving chemotherapy and use of continuous glucose monitoring (CGM) in new clinical settings. Along with colleagues at IDC, he continues working on the standardization of glucose reports using the Ambulatory Glucose Profile (AGP). Finally, Dr Carlson recently received a grant from JDRF to investigate the use of intranasal insulin as a therapeutic approach to treating hypoglycemia unawareness in patients with type 1 diabetes.
Prior to working at IDC, as a practicing endocrinologist he helped launch a telehealth program in partnership with primary care and diabetes education based on the model of “training-the-trainer”, and remains active in that program to this day. He completed endocrinology, diabetes and metabolism fellowship at the University of Vermont.
Dr. Carlson has been involved at the national level as a member of the American Diabetes Association’s Prevention Committee and also in the Endocrine Society’s Task Force for Technology in T1D. He has published several papers related to diabetes, including a review of the use of CGM in T2D. He has been named a “Rising Star” physician in Minneapolis/St. Paul and as a “Best Doctor” in Minnesota Monthly.
Disclosures
HealthPartners Institute/Park Nicollet Health Services employs Anders L. Carlson, MD and has contracts with the listed companies for his services as a research investigator and/or consultant. No personal income from any of these services goes to Dr. Carlson: Consulting/Advisory Board & Clinical Investigator - Novo Nordisk, Medtronic, Insulet, Sanofi and Clinical Investigator only: Dexcom & Abbott.Recent Contributions to PracticeUpdate:
- Continuous Glucose Monitoring–Derived Metrics, A1C, and Risk of Hypoglycemia in Older Adults With T1D
- Improved Glycemic Variability and Time in Range With Dapagliflozin vs Gliclazide Modified-Release Among Adults With Type 2 Diabetes Evaluated by CGM
- Iterative Changes in Medtronic Hybrid Closed-Loop Algorithm Improved Performance